Core Viewpoint - On October 9, Sunshine Nuohuo experienced a decline of 2.85% with a trading volume of 240 million yuan, indicating a potential concern regarding its stock performance [1]. Financing Summary - On October 9, Sunshine Nuohuo had a financing buy-in amount of 45.86 million yuan, with a net financing buy of 109,600 yuan, while the total financing and securities balance reached 518 million yuan, accounting for 7.20% of its market capitalization [1]. - The financing balance of 518 million yuan is above the 70th percentile level over the past year, indicating a relatively high level of financing activity [1]. Securities Lending Summary - On October 9, there were no shares repaid or sold in securities lending, with a total lending balance of 0 shares, which is above the 80th percentile level over the past year, suggesting a high level of lending activity [1]. Company Overview - Sunshine Nuohuo, established on March 9, 2009, and listed on June 21, 2021, is located in Beijing and specializes in generic drug development, consistency evaluation, and innovative drug development, with 99.91% of its revenue coming from CRO services [1]. - As of June 30, the number of shareholders increased by 18.76% to 8,621, while the average circulating shares per person decreased by 15.80% to 12,991 shares [2]. Financial Performance - For the first half of 2025, Sunshine Nuohuo reported a revenue of 590 million yuan, representing a year-on-year growth of 4.87%, while the net profit attributable to shareholders decreased by 12.61% to 130 million yuan [2]. Dividend Information - Since its A-share listing, Sunshine Nuohuo has distributed a total of 105 million yuan in dividends, with 84.29 million yuan distributed over the past three years [3]. Institutional Holdings - As of June 30, 2025, the fourth largest circulating shareholder is Rongtong Health Industry Flexible Allocation Mixed A/B, holding 2.55 million shares, a decrease of 58,600 shares from the previous period [3].